All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Homocysteine (HCY) is a non-proteogenic thiol amino acid, which is generated from the methionine metabolism through demethylation \[[@pone.0202567.ref001]\]. The enzyme methionine-synthase catalyzes the reconstitution of HCY to methionine \[[@pone.0202567.ref001]--[@pone.0202567.ref003]\]. This biochemical reaction is mediated by the cofactors folic acid (FA) and vitamin B12, and reduced availability of these vitamins may result in increased HCY levels \[[@pone.0202567.ref004]\].

Recently published studies showed that elevated HCY concentrations are associated with depression \[[@pone.0202567.ref005], [@pone.0202567.ref006]\]. Moreover, elevated HCY levels have the potential to modulate neurotransmitters (e.g., dopamine, serotonin, melatonin) and dysregulate neurons, thereby increasing the risk of depression \[[@pone.0202567.ref007], [@pone.0202567.ref008]\]. Additionally, low FA plasma levels were found to be related with the diagnosis of major depression \[[@pone.0202567.ref009]\] and poorer clinical response to antidepressant treatment \[[@pone.0202567.ref007], [@pone.0202567.ref010]\]. Also, vitamin B12 was reported to have an inverse relationship with the risk of depressed symptoms \[[@pone.0202567.ref011], [@pone.0202567.ref012]\].

While current literature suggests these associations between vitamin B12, FA and HCY metabolism and depressive disorder, the nature of the relationship between elevated HCY blood levels and depression remains unclear \[[@pone.0202567.ref006]\]. There is some evidence, however, that increased HCY levels are the consequence rather than the cause of depression \[[@pone.0202567.ref013]\]. The question raises which underlying causative mechanisms influence the HCY metabolism in individuals with depression.

Currently malnutrition \[[@pone.0202567.ref014]\] and carbohydrate malabsorption \[[@pone.0202567.ref015]\] are proposed gastrointestinal conditions that lower the human FA status, thereby increasing the plasma HCY concentration. Moreover, Ledochowski et al. found lactose malabsorption linked to early signs of depression \[[@pone.0202567.ref016]\]. Primary adult-type lactose malabsorption (PALM) is an autosomal recessive gastrointestinal condition with declined lactase activity in the brush boarder of the small intestine \[[@pone.0202567.ref017]--[@pone.0202567.ref019]\]. Genotyping for the single-nucleotide polymorphism (C/T-13910) of the lactase gene (*LCT*) has been used to identify individuals with lactase non-persistence \[[@pone.0202567.ref018], [@pone.0202567.ref019]\]. The undigested non-absorbable lactose reaches the colon, where toxic bacterial degradation metabolites are formed. Interference of these microbial metabolic products with the neurotransmitter metabolism may be one explanation for the development of depression in individuals with PALM \[[@pone.0202567.ref016]\], however, the exact underlying biological mechanisms remain unclear.

Therefore, this study was conducted to evaluate possible associations between HCY, FA and vitamin B12 plasma levels in 78 patients with PALM and 160 individuals with lactase persistence sub-grouped by the presence or absence of major depression.

Materials and methods {#sec006}
=====================

Study design and patients {#sec007}
-------------------------

A total of 238 study participants were included in this prospective cohort study. The main demographic and clinical characteristics are summarized in [Table 1](#pone.0202567.t001){ref-type="table"}. The median age was 41.5 (range: 16--70) years, and 66.0% of participants were female.
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###### Main demographic and clinical characteristics.

![](pone.0202567.t001){#pone.0202567.t001g}

                                                Study population (n = 238)
  --------------------------------------------- ----------------------------
  **Demographic characteristics**:              
  **Female (%)**                                66.0 (n = 157)
  **Male (%)**                                  34.0 (n = 81)
  **Mean age (years)**                          41.0 ± 14.4
  **Anthropometric data**:                      
  **Height (m)**                                1.7 (1.64--1.78)
  **Weight (kg)**                               73.0 (60.0--85.2)
  **BMI (kg/m**^**2**^**)**                     24.22 (21.63--28.09)
  ***LCT* C/T**~**-13910**~ **polymorphism**:   
  **C/C**~**-13910**~ **homozygotes (%)**       32.8 (n = 78)
  **C/T**~**-13910**~ **heterozygotes (%)**     42.8 (n = 102)
  **T/T**~**-13910**~ **homozygotes (%)**       24.4 (n = 58)
  **Psychiatric disorder**:                     
  **Major depression (%)**                      33.6 (n = 80)
  **Non depression (%)**                        66.4 (n = 158)
  **Depressive symptoms**:                      
  **BDI-II score**                              9.0 (3.0--18.0)
  **Laboratory parameters**:                    
  **Creatinine (mg/dL)**                        0.72 ± 0.12
  **eGFR (mL/min/1.73m**^**2**^**)**            108.7 ± 15.28
  **Homocysteine (μmol/L)**                     9.0 (7.9--10.3)
  **Folic acid (ng/mL)**                        6.7 (4.9--9.8)
  **Vitamin B12 (pg/mL)**                       398 (299.8--470.1)

BMI = body mass index; eGFR = estimated glomerular filtration rate; BDI-II = Beck Depression Inventory. Data are presented as percentage, means ± standard deviation, or medians (Q1 --Q3).

The study population consisted of 80 patients with major depression, diagnosed and treated at the Department of Psychiatry (General Hospital Steyr, Steyr, Austria), and 158 healthy individuals without depressive symptomatology or a former history of psychiatric disorder. All participants underwent genotyping for the lactase *LCT* C/T~-13910~ polymorphism and blood-sampling after an overnight fasting state in the morning evaluating plasma levels of HCY, FA and vitamin B12, and the kidney function (i.e., creatinine, estimated glomerular filtration rate \[eGFR\]). Additionally, the assessment of depressive symptoms was carried out with the self-rating Beck Depression Inventory (BDI-II) questionnaire \[[@pone.0202567.ref020]\]. Anthropometric data (weight, height and body mass index \[BMI\]) were determined using a calibrated personal scale and a wall-mounted metric tape.

None of the included patients had vitamin B12 or FA supplementation. Individuals with impaired renal function were excluded from the study.

All participants gave their written informed consent. This study was approved by the Ethical Committee of the Johannes Kepler University Linz (Linz, Austria) and carried out according to the latest version of the Declaration of Helsinki.

Laboratory analyses {#sec008}
-------------------

VACUETTE^®^ K3EDTA tubes (2 mL) (Greiner Bio-One International GmbH, Kremsmünster, Austria) were used for *LCT* C/T~-13910~ genotyping. Genomic DNA was extracted from 200 μL EDTA blood with the Nucleic Acid Isolation Kit I on the MagNA Pure Compact Instrument (Roche Diagnostics, Vienna, Austria) according to the manufacturer's instructions. Genotyping for the *LCT* C/T~-13910~ polymorphism was performed by real-time PCR and melting curve analysis (*LCT* T-13910C ToolSet^™^ \[Roche Diagnostics\]) on a LightCycler 2.0 Instrument (Roche Diagnostics) \[[@pone.0202567.ref021]\].

Fasting blood samples were drawn into VACUETTE^®^ LH lithium tubes (4 mL) and centrifuged at 2000 x g for 10 minutes. HCY (normal range: 3.2--10.7 μmol/L), FA (normal range 3.1--17.5 ng/mL) and vitamin B12 (normal range: 182--625 pg/mL) measurements were performed by competitive chemiluminescent immunoassays on a Dimension Vista^®^ 1500 System (Siemens Healthcare GmbH; Vienna, Austria). Creatinine (male: 0.7--1.3 mg/dL; female: 0.55--1.02 mg/dL) was measured using an enzymatic method applied on a Roche Cobas Mira (Roche Diagnostics, Vienna, Austria). The eGFR (normal: \>70 mL/min/1.73m2) was calculated applying the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \[[@pone.0202567.ref022]\].

Statistical analysis {#sec009}
--------------------

Descriptive statistics were used to present study variables. The Kolmogorov-Smirnov test was performed to calculate data distribution. Normally distributed continuous variables were given as means ± standard deviation (SD), and not normally distributed data as medians with interquartile ranges (Q1 --Q3). Categorical variables were expressed as percentages.

For subgroup comparisons of metric variables in case of normal distribution the independent two-sample Student's *t*-test was used, in case of non-normal distributed variables, the exact Mann-Whitney *U*-test was calculated. Pearson's correlation analyses were calculated to assess possible positive or negative correlations between HCY and other study parameters. A p-value of \< 0.05 was considered statistically significant. For all statistical analyses, the Analyse-it^®^ software version 4.92 (Analyse-it Software, Ltd., Leeds, United Kingdom) was used.

Results {#sec010}
=======

Study population {#sec011}
----------------

The observed frequencies for the *LCT* C/T~-13910~ polymorphism are given in [Table 1](#pone.0202567.t001){ref-type="table"}. Seventy-eight out of 238 (32.8%) study participants could be identified as C/C~-13910~ homozygotes, the *LCT* genotype indicative of PALM. A total of 102/238 (42.8%) and 58/238 (24.4%) individuals were C/T~-13910~ hetero- and T/T~-13910~ homozygotes, respectively, with both genotypes indicating lactase persistence. All in all, 22/78 patients (28.2%) with PALM and 58/160 (36.3%) individuals with lactase persistence were diagnosed with major depression.

HCY, FA and vitamin B12 measurements {#sec012}
------------------------------------

No significant differences of median (interquartile ranges) HCY (9.15 \[8.0--11.06\] vs. 8.9 \[7.79--10.20\] μmol/L, p = 0.174), FA (6.75 \[4.64--9.22\] vs. 6.7 \[5.09--10.32\] ng/mL, p = 0.412), and vitamin B12 plasma levels (402.5 \[301.4--467.2\] vs. 396.5 \[298.0--472.3\] pg/mL, p = 0.848) were observed between 80 patients with major depression compared to 158 individuals without depression, respectively.

However, plasma HCY levels were positively correlated with the BDI-II score (p = 0.052, Pearson's correlation coefficient \[r\] = 0.126) and creatinine (p \< 0.001, r = 0.237) and showed a negative correlation with FA (p = \< 0.001, r = - 0.313), with vitamin B12 (p = 0.029, r = -0.141), and with the eGFR (p = 0.001, r = - 0.205), respectively.

As shown in [Table 2](#pone.0202567.t002){ref-type="table"}, 22 depressed patients with PALM had significantly higher median (interquartile range) HCY plasma levels (10.10 \[8.46--12.03\] vs. 8.9 \[7.54--9.86\] μmol/L, p = 0.029) compared to 56 non-depressed individuals with PALM. Interestingly, no significant differences of plasma HCY, FA and vitamin B12 concentrations were found for 58 depressed and 102 non-depressed individuals with lactase persistence (HCY: 8.9 \[7.9--10.41\] vs. 9.0 \[7.8--10.51\] μmol/L, p = 0.862; FA: 7.0 \[4.6--9.33\] vs. 6.5 \[4.99--10.01\] ng/mL, p = 0.798; vitamin B12: 377.0 \[282.3--441.5\] vs. 384.5 \[297.9--470.8\] pg/mL, p = 0.509), respectively.

10.1371/journal.pone.0202567.t002

###### Comparison of study parameters for 22 depressed and 56 non-depressed individuals with primary-adult lactose malabsorption (PALM).
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                                       Depression             Non depression         p-value
  ------------------------------------ ---------------------- ---------------------- ----------
  **Mean age (years)**                 38.9 ± 12.2            39.3 ± 13.5            0.906
  **Height (m)**                       1.68 (1.65--1.78)      1.69 (1.62--1.74)      0.466
  **Weight (kg)**                      82.5 (64.6--92.1)      73.0 (61.0--79.0)      0.090
  **BMI (kg/m**^**2**^**)**            26.49 (27.71--32.0)    24.19 (22.29--26.93)   0.168
  **Creatinine (mg/dL)**               0.73 ± 0.13            0.72 ± 0.12            0.841
  **eGFR (mL/min/1.73m**^**2**^**)**   108.42 ± 15.98         109.81 ± 14.04         0.705
  **Homocysteine (μmol/L)**            10.10 (8.46--12.03)    8.9 (7.54--9.86)       0.029
  **Folic acid (ng/mL)**               5.7 (4.68--9.14)       6.95 (5.24--10.56)     0.272
  **Vitamin B12 (pg/mL)**              423.0 (386.8--470.4)   405.5 (308.3--474.3)   0.444
  **BDI-II score**                     28.0 (21.9--38.0)      5.0 (2.0--8.0)         \< 0.001

BMI = body mass index; eGFR = estimated glomerular filtration rate; BDI-II = Beck Depression Inventory. Data are presented as means ± standard deviation or medians (Q1--Q3).

The box-and whisker plots of HCY, FA and vitamin B12 measurements for 78 individuals with PALM are illustrated in [Fig 1(a)--1(c)](#pone.0202567.g001){ref-type="fig"}.

![Box-and-whisker plots of (a) homocysteine, (b) folic acid, and (c) vitamin B12 plasma level comparisons between 22 depressed and 56 non-depressed individuals with primary-adult lactose malabsorption (PALM) (p-values were 0.029, 0.272, and 0.444).\
The central boxes represent the 25^th^ to 75^th^ percentile range. The lines inside the boxes show the median value for each group.](pone.0202567.g001){#pone.0202567.g001}

Discussion {#sec013}
==========

The current work investigated 78 subjects with PALM and 160 individuals with lactase persistence sub-grouped by the presence or absence of major depression for their HCY, FA and vitamin B12 plasma levels. To the best of our knowledge, this is the first study addressing a possible association between total plasma HCY and depression in individuals with PALM. We found patients with major depression and PALM to have significantly higher plasma HCY (10.10 \[8.46--12.03\] vs. 8.9 \[7.54--9.86\] μmol/L, p = 0.029) and lower FA plasma levels (5.7 \[4.68--9.14\] vs. 6.95 \[5.24--10.56\], p = 0.272) compared to non-depressed subjects with PALM. These associations, however, were not observed in individuals with lactase persistence. One possible explanation for this finding could be that carbohydrate malabsorption leads to changes in the bacterial colonization of the gastrointestinal tract \[[@pone.0202567.ref015]\]. Since the human intestinal flora is capable of synthesizing FA, which plays an important physiological role in the plasma FA concentrations and metabolism of healthy individuals \[[@pone.0202567.ref023]\], an altered bacterial composition in the gut could attribute to lower plasma FA levels in individuals with carbohydrate malabsorption \[[@pone.0202567.ref015]\]. In general, lower FA levels have been observed more frequently in patients with depression than in healthy controls \[[@pone.0202567.ref024], [@pone.0202567.ref025]\]. Changes in dietary habits may contribute to nutritional FA deficiency with decreased FA concentrations in these patients. \[[@pone.0202567.ref025], [@pone.0202567.ref026]\].

Elevated HCY plasma levels may occur as a result of decreased plasma FA concentrations because FA plays an important role as methyl-group donator for the conversion of HCY to methionine \[[@pone.0202567.ref027], [@pone.0202567.ref028]\]. Nevertheless, the diagnosis of functional FA deficiency may be uncertain by determining the plasma FA concentration alone because acute dietary high intake or restriction of this vitamin can influence its plasma levels independently of the intracellular stores \[[@pone.0202567.ref026]\]. Even the determination of red cell FA, which can be influenced by some analytical variables (e.g., hematocrit, oxygen saturation of hemoglobin), could not be confirmed as a better predictor of a patient's FA status in clinical practice \[[@pone.0202567.ref029]\].

Current literature suggests total plasma HCY as a sensitive parameter to predict FA or vitamin B12 deficiency \[[@pone.0202567.ref026]\]. Regarding the present study population, plasma HCY levels showed a significant negative correlation with the FA (p = \< 0.001, r = -0.313) and the vitamin B12 (p = 0.029, r = - 0.141) profile. This finding is in line with previous studies reporting an inverse relationship for these biomarkers \[[@pone.0202567.ref030], [@pone.0202567.ref031]\].

Here, plasma HCY levels correlated modestly with depressive symptoms (p = 0.052, r = 0.126). In comparison, other studies suggested a significant positive relationship for the severity of depressive symptoms and HCY concentrations \[[@pone.0202567.ref026], [@pone.0202567.ref032]--[@pone.0202567.ref034]\]. All these observations support the notion that there might be an association between HCY metabolism and depression. However, here we observed significant differences in median plasma HCY levels between subjects with and without major depression in the patient PALM subgroup, only. These findings indicate, that also other underlying pathophysiological factors, such as carbohydrate malabsorption, might be associated with elevated HCY levels and depression.

The major limitation of this cross-sectional study is the relatively low number of patients used to generate strong associations with biologically relevance. Furthermore, fructose malabsorption and dietary habits of study participants were not considered in the study design. Follow-up studies with large cohorts of patients comparing HCY, FA and vitamin B12 levels in a setting with and without different forms of carbohydrate malabsorption are warranted in order to fully elucidate possible associations between malabsorption syndromes, hyperhomocysteinemia and depression.

Conclusions {#sec014}
===========

Depressed individuals with PALM showed significantly higher HCY and lower FA levels compared to non-depressed individuals with PALM, however, this association was not observed in individuals with lactase persistence. These findings suggest a link between increased HCY levels, lactose malabsorption and depression.

Supporting information {#sec015}
======================

###### The data set of the study is provided.

(XLSX)
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Click here for additional data file.
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